Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
CD33 Double Nickase Plasmid (h): sc-401011-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- CD33 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- CD33 Double Nickase Plasmid (h) and CD33 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting CD33. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: CD33 Antibody (6C5/2): sc-53199
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CD33 Double Nickase Plasmid (h) | sc-401011-NIC | 20 µg | $410.00 | |||
CD33 Double Nickase Plasmid (h2) | sc-401011-NIC-2 | 20 µg | $410.00 |
CD33 (Siglec-3) is a sialic acid–binding immunoglobulin-like lectin expressed predominantly on myeloid lineage cells, where it functions as an inhibitory receptor that dampens immune activation. Through immunoreceptor tyrosine-based inhibitory motif (ITIM) signaling and recruitment of phosphatases such as SHP-1/2, CD33 modulates downstream pathways controlling cytokine production, phagocytosis, and cellular activation thresholds. CD33 participates in regulation of innate immune homeostasis and microglial responses, linking glycan recognition to inhibitory signaling programs. Altered CD33 expression or function has been implicated in myeloid malignancies and neuroinflammatory processes, making it a useful target for mechanistic studies of immune regulation and disease-associated myeloid phenotypes.
CD33 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the CD33 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within CD33. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt CD33 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of CD33-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.